A next generation, global biopharmaceutical company

TopAlliance Biosciences is an innovation-driven biopharmaceutical company dedicated to the discovery and development of innovative drugs and their clinical research and commercialization on a global scale. Since our establishment in December 2012, leveraging our advanced R&D platforms and globally integrated R&D process, we have developed a collection of drug candidates that we believe to have solid biological mechanisms.

Our parent company, Shanghai Junshi Biosciences, is the first innovative drug company in China to obtain the approval for the marketing of anti-PD-1 monoclonal antibody in China and the first company to obtain approval for clinical trial for anti-PCSK9 monoclonal antibody and anti-BLyS monoclonal antibody among the Chinese companies.

Our flagship therapy TUOYI ( Toripalimab) – an anti-PD-1 monoclonal antibody injection), the first product marketed by the Company, has delivered impressive clinical data, and has shown satisfying efficacy and safety on various indications.